Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis
Authors' conclusion
Our study indicated a significant perturbation in oxylipin metabolism among patients with PHO, with distinct metabolic signatures observed between PHOAR1 and PHOAR2. The disruption extended beyond the metabolism of PGE2. It encompassed a broader alteration across the polyunsaturated fatty acid metabolism spectrum, including various eicosanoids and oxylipins. Our work provided a comprehensive understanding of the pathogenesis of PHO, and underscored the potential for subtype-specific therapeutic interventions.
Study context
- Population
- Patients with primary hypertrophic osteoarthropathy (PHOAR1 and PHOAR2 subtypes); serum collected at diagnosis
- Participants
- 16 vs 16
- Comparison
- Patients with primary hypertrophic osteoarthropathy (PHO) vs healthy controls
- PHOn = 16
- Healthy controlsn = 16reference
- Outcome
- Oxylipin networks in PHO and their associations with clinical characteristics
- Follow-up
- At diagnosis
Methodological detailsage- and sex-matched healthy controls
- Age- and sex-matched healthy controls
Main finding
As reported in the abstract
Oxidized lipid metabolites identified
About 60
Differentially expressed in PHO
19
Observational data: associations, not effects.
Further findings
Correlation of oxylipins with clinical features
- Oxylipin metabolites associated with clinical features, including bone microarchitecture
Subtypes PHOAR1 vs PHOAR2
- Oxylipin profiles differed between PHOAR1 and PHOAR2, suggesting distinct metabolic signatures
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →